-
Oramed Advancing Oral Insulin Program Independently; Announces Launch of New
U.S. Trial - Diversified Investment Portfolio Delivers Strong Returns
-
Company
Accelerating Growth Through Strategic Partnerships, Innovation, and Value-Driven Expansion - Company Reaffirms Commitment to Rewarding Shareholders, Including Plans for a One-Time Dividend
Dear Shareholders,
I am pleased to share with you some of the significant developments we have seen across Oramed’s operations and strategic initiatives. Over the past year, we have advanced our core programs while simultaneously building a diversified portfolio of opportunities that demonstrate our commitment to creating long-term shareholder value.
We have leveraged our strengths, including our deep industry relationships, insights, and operational expertise, to identify and capitalize on high-conviction investment opportunities across the biomedical landscape. This diversified approach has generated substantial returns while maintaining our focus on advancing our refined oral insulin program based on the high-responder subgroups we identified through extensive data analysis.
Oral Insulin Program
Following our extensive deep-dive analysis of Phase 2 and Phase 3 data, we identified high-responder subgroups that demonstrated particularly encouraging results. These subgroups, including participants with lower BMI and older demographics, showed the possibility of achieving over 1% reduction in HbA1c, a clinically meaningful outcome that potentially strengthens our regulatory and commercial positioning.
We are initiating a 60-patient, US-based trial. We believe this approach will allow us to validate the robustness of our oral insulin formulation while providing valuable data to potential partners. The trial was designed to use the smallest adequately powered population expected to obtain such validation in what we believe to be the shortest time possible, providing a cost-effective way to generate additional compelling evidence and refine our patient selection criteria for future potential regulatory submissions.
The previously announced joint venture with
Investment Portfolio
Over the past two years, Oramed has made strategic investments in a diversified portfolio of innovative biomedical companies, each selected for their potential to generate substantial returns while complementing our core competencies:
Alpha Tau Medical Ltd (“Alpha Tau”) Alpha Tau is pioneering a revolutionary approach to cancer treatment through its
We made an initial investment of
Beyond the immediate appreciation, we believe Alpha Tau represents an exceptional long-term opportunity with multiple transformative clinical and commercial inflection points ahead. We believe their revolutionary alpha radiation therapy technology positions them for significant value creation as they advance through pivotal clinical milestones and move toward commercialization across multiple indications.
As part of our involvement, we entered into an investor relations and business advisory agreement valued at
Shareholders interested in receiving updates directly from Alpha Tau can visit their investor relations page at https://www.alphatau.com/news-pr.
BioXcel Therapeutics
, Inc. (“
Pelthos
We invested
Additional Investments: In addition to the investments detailed above, we maintain small positions in earlier-stage biotech investments that continue to be part of our diversified portfolio of strategic investments. Additionally, as part of our capital management strategy, we have invested and loaned approximately
Dividend Update
In connection with our previously announced joint venture, we discussed providing shareholders with a one-time dividend. While we have decided to continue our oral insulin program independently without the spin-off, we remain committed to rewarding our shareholders.
Upcoming Growth Initiative
Building on our investment track record, we are actively pursuing partnerships with strong companies possessing significant potential, as we have demonstrated with Alpha Tau, Scilex, and our other portfolio companies. We leverage our extensive network, regulatory expertise, and business development capabilities to actively shape these companies’ growth trajectories and help unlock their full market potential. We are continuously working to identify and execute on potential opportunities that can drive substantial value creation.
In Conclusion, we believe the numbers speak for themselves:
In
We believe Oramed stands at a unique inflection point, with our core oral insulin program showing renewed promise through our refined subgroup analysis while our investment portfolio demonstrates our ability to identify and capitalize on emerging opportunities. We believe our multi-faceted approach, combining clinical development, partnerships, and prudent capital deployment across diversified assets, positions us to create sustainable value across diverse market opportunities.
Thank you for your continued support as we execute on this expanded growth strategy. We look forward to sharing more detailed updates on our progress in the coming quarters.
Sincerely,
About
Forward-looking statements: This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, we are using forward-looking statements when we discuss our trial plans, expected returns from our investment portfolio, our growth initiatives, potential partnerships, dividend plans, and our ability to create shareholder value through our diversified approach. These forward-looking statements are based on the current expectations of the management of Oramed only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval; competition from other pharmaceutical or biotechnology companies; market volatility affecting our investment portfolio; our ability to realize expected returns from Scilex and other investments; and our ability to identify and execute partnerships. Except as otherwise required by law, Oramed undertakes no obligation to publicly release any revisions or updates to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
Company Contact:
+1-844-9-ORAMED
ir@oramed.com
Logo – https://mma.prnewswire.com/media/1724339/Oramed_Logo.jpg
View original content:SOURCE